CoChat

Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs?

Klitgaard, Henrik · 2001 · Epilepsia
Cited by 148

The DOI matches its Crossref record.

Abstract

Summary:Levetiracetam is a new antiepileptic drug (AED) devoid of anticonvulsant activity in the two classic screening models for AEDs, the maximal electroshock and pentylenetetrazol seizure tests in both mice and rats. This contrasts a potent seizure suppression in genetic and kindled mice and rats and against chemoconvulsants inducing partial seizures in rats. The highly selective action in “epileptic” animals distinguishes levetiracetam from classic and other new AEDs that have nearly equipotent effects in normal and “epileptic” animals. Levetiracetam induces minor behavioral alterations in normal and in kindled mice and rats. This results in an unusually high safety margin in animal models reflecting both partial and primary generalized epilepsy. Furthermore, experiments in the kindling model suggest that levetiracetam may possess antiepileptogenic properties due to a potent ability to prevent the development of kindling in mice and rats at doses devoid of adverse effects. Electrophysiologic recordings from different experimental models suggest that levetiracetam exerts a selective action against abnormal patterns of neuronal activity, which probably explains its selective protection in epileptic animals and its unique tolerability. This effect appears to derive from one or more novel mechanisms of action that do not involve a conventional interaction with traditional drug targets implicated in the modulation of inhibitory and excitatory neurotransmission. Instead, ligand‐binding assays have disclosed a brain‐specific binding site for levetiracetam. These studies reveal a unique preclinical profile of levetiracetam, distinct from that of all known AEDs, suggesting that levetiracetam could represent the first agent in a new class of AEDs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1528-1167.2001.00003.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 28

  1. 10.1016/0014-2999(92)90855-X · DOI · Paper page
  2. 10.1016/S0014-2999(98)00410-5 · DOI · Paper page
  3. 10.1016/0014-2999(93)90768-D · DOI · Paper page
  4. Food and Drug Administration.FDA approves new epilepsy drug.Rockville Md: National Press Office; December 1 1999. FDA Talk Paper T99‐54.
  5. 10.1016/0014-4886(69)90128-9 · DOI · Paper page
  6. 10.1016/0165-0173(87)90002-6 · doi:10.1016/0165-0173(87)90002-6
  7. 10.1016/0024-3205(81)90659-7 · DOI · Paper page
  8. 10.1016/0166-4328(83)90136-5 · DOI · Paper page
  9. 10.1111/j.1528-1157.1980.tb04321.x · DOI · Paper page
  10. 10.1016/0014-4886(86)90160-3 · DOI · Paper page
  11. 10.1002/ana.410160712 · DOI · Paper page
  12. 10.1016/S0920-1211(00)00108-X · DOI
  13. 10.1016/0920-1211(95)00077-1 · DOI · Paper page
  14. Löscher W, 1991, Anticonvulsant and behavioral effects of two novel competitive N‐methyl‐d‐aspartic acid receptor antagonists, CGP 37849 and CGP 39551, in the kindling model of epilepsy. Comparison with MK‐801 and carbamazepine., J Pharmacol Exp Ther, 256, 432, 10.1016/S0022-3565(25)22942-1 · DOI · Paper page
  15. 10.1016/0920-1211(93)90031-2 · DOI · Paper page
  16. 10.1006/ebeh.2000.0098 · DOI
  17. Löscher W, 1998, Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy., J Pharmacol Exp Ther, 284, 474, 10.1016/S0022-3565(24)37251-9 · DOI · Paper page
  18. 10.1007/PL00005097 · DOI
  19. 10.1016/0014-2999(95)00597-8 · DOI
  20. 10.1038/sj.bjp.0701476 · doi:10.1038/sj.bjp.0701476
  21. Margineanu DG Klitgaard H. Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs.Pharmacol Res(in press).
  22. Klitgaard H, 1999, Levetiracetam counteracts propagation of epileptiform activity induced by systemic administration of pilocarpine and kainic acid to rats in vivo [Abstract]., Epilepsia, 40, 138
  23. 10.1016/0014-2999(95)00436-O · DOI · Paper page
  24. Zona C Niespodziany I Marchetti C et al. Levetiracetam does not modulate neuronal voltage‐gated Na+and T‐type Ca2+currents.Seizure(in press).
  25. Niespodziany I, 2000, Levetiracetam: modulation of high voltage activated Ca2+ current in Ca1 pyramidal neurons of rat hippocampal slices [Abstract]., Epilepsia, 41, 37
  26. Madeja M, 2001, Effect of levetiracetam on voltage‐gated potassium channels: a novel antiepileptic mechanism of action [Abstract]?, Epilepsia, 42, 19
  27. Rigo JM, 2000, Levetiracetam: novel modulation of ionotropic inhibitory receptors [Abstract]., Epilepsia, 41, 35
  28. 10.1111/j.1528-1157.1986.tb05743.x · doi:10.1111/j.1528-1157.1986.tb05743.x

Cited by

See all 148

Metadata

Authors
Klitgaard, H.
Venue
Epilepsia
Publisher
Wiley
Published
2001-08
Volume
42
Issue
s4
Pages
13-18
ISSN
  • 0013-9580 (ISSN-L)
  • 1528-1167
OpenAlex
W2069703883
Cited by
148
References
0
FWCI
5.88
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs? https://app.cochat.ai/papers/10.1111/j.1528-1167.2001.00003.x
The paper
Klitgaard, H. (2001). Levetiracetam: The Preclinical Profile of a New Class of Antiepileptic Drugs? Epilepsia. https://doi.org/10.1111/j.1528-1167.2001.00003.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.